Differential Effector Engagement by Oncogenic KRAS.

doi:10.1016/j.celrep.2018.01.051

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Differential Effector Engagement by Oncogenic KRAS.

Cell reports - 13 Feb 2018

Yuan Tina L, Amzallag Arnaud, Bagni Rachel, Yi Ming, Afghani Shervin, Burgan William, Fer Nicole, Strathern Leslie A, Powell Katie, Smith Brian, Waters Andrew M, Drubin David, Thomson Ty, Liao Rosy, Greninger Patricia, Stein Giovanna T, Murchie Ellen, Cortez Eliane, Egan Regina K, Procter Lauren, Bess Matthew, Cheng Kwong Tai, Lee Chih-Shia, Lee Liam Changwoo, Fellmann Christof, Stephens Robert, Luo Ji, Lowe Scott W, Benes Cyril H, McCormick Frank

Abstract excerpt

KRAS can bind numerous effector proteins, which activate different downstream signaling events. The best known are RAF, phosphatidylinositide (PI)-3' kinase, and RalGDS families, but many additional direct and indirect effectors have been reported. We have assessed how these effectors contribute to several major phenotypes in a quantitative way, using an arrayed combinatorial siRNA screen in which we knocked down...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenylate Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to AMP-Activated Protein Kinase Kinases

Share to Drug Evaluation, Preclinical

Share to Metabolic Networks and Pathways

Share to Oncogenes

Share to RNA Interference

Share to RNA, Small Interfering

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 29444439
DOI: 10.1016/j.celrep.2018.01.051
PMCID: PMC6343826

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential Effector Engagement by Oncogenic KRAS.PMID 29444439Read ↗

Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.Semantic proximity Read ↗

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Oncogenic KRAS signalling in pancreatic cancerSemantic proximity Read ↗

Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.Semantic proximity Read ↗

Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass.Semantic proximity Read ↗

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.Semantic proximity Read ↗

Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.Semantic proximity Read ↗

The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.Semantic proximity Read ↗

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read ↗

Survival of pancreatic cancer cells lacking KRAS functionSemantic proximity Read ↗

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survivalSemantic proximity Read ↗

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.